Advertisement

Topics

Daiichi Sankyo Ends Biosimilar Enbrel Partnership with Coherus in Japan

06:06 EDT 5 Jul 2017 | Genetic Engineering News

Daiichi Sankyo said today it was ending its co-development in Japan with Coherus BioSciences of a biosimilar to Amgen’s marketed drug Enbrel ® (etanercept) for rheumatoid arthritis, ending a five-year-old partnership by the companies. The decision came three weeks after the FDA rejected Coherus’ Biologics License Application for a copycat biologic to Amgen’s Neulasta ® (pegfilgrastim) in the U.S., leading to Coherus laying off 30% of its workforce. The Enbrel biosimilar CHS-0214 met its primary endpoint of equivalence with Enbrel in rheumatoid arthritis as well as in psoriasis, following Phase III trials in November 2015 and January 2016, respectively, Coherus disclosed in its Form 10-K annual report for 2016, filed March 14. Today in a terse statement, the Japanese pharma said the partnership was ending “due to the fact that a commercial manufacturing process to enable the feasible supply of CHS-0214 in Japan cannot be ...

Original Article: Daiichi Sankyo Ends Biosimilar Enbrel Partnership with Coherus in Japan

NEXT ARTICLE

More From BioPortfolio on "Daiichi Sankyo Ends Biosimilar Enbrel Partnership with Coherus in Japan"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...